Psychedelic Research in
United Arab Emirates
The United Arab Emirates has a tightly regulated psychedelic access environment, with Blossom currently linking one esketamine-related trial but no local stakeholders or events. The page is best framed around controlled medical access and specialist psychiatric settings rather than a broad psychedelic research ecosystem.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in United Arab Emirates.
- 1
Blossom currently links the United Arab Emirates to one esketamine-related trial and no local psychedelic stakeholders or events.
- 2
Classic psychedelics should be framed within strict narcotic and psychotropic controls rather than general medical availability.
- 3
Esketamine is the clearest psychedelic-adjacent medical signal, especially for treatment-resistant depression services.
- 4
Access appears specialist-led and institution-specific, with reimbursement and prior-authorisation details requiring separate verification.
- 5
Future updates should monitor UAE Drug Establishment, Ministry of Health, hospital-service, and trial-registry sources.
Research Snapshot
Blossom currently tracks 1 psychedelic clinical trial connected to the United Arab Emirates.
- Active trials
- 0
- Total trials
- 1
- Stakeholders
- 0
- Events
- 0
None marked active
Country-linked records
No linked stakeholders
No linked events
Top Compounds
- Esketamine(1)
Top Study Topics
- Treatment-Resistant Depression (TRD)(1)
Medical Access Snapshot
The United Arab Emirates maintains strict national controls on classic recreational psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, ibogaine, ayahuasca, 5-MeO-DMT), which are effectively prohibited outside of approved research. At the same time, pharmaceutical derivatives developed for medical use - notably esketamine (Spravato) - have been licensed/introduced into UAE clinical settings under Ministry of Health supervision, but access is typically limited to specialist clinics/private hospitals and reimbursement is uncommon or highly restricted...
Regulatory Status
Access in the United Arab Emirates is best described as medical-only and tightly restricted. Federal drug-control and medical-products rules govern narcotic and psychotropic substances, prescribing, supply, and tracking. Classic psychedelics should be treated as prohibited or research-only unless a specific authorisation is verified, while esketamine and ketamine may be relevant in regulated specialist settings. Public evidence was not sufficient to make broad claims about reimbursement or routine psychiatric ketamine access.
Country Details
- Region
- Asia
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
The United Arab Emirates maintains strict national controls on classic recreational psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, ibogaine, ayahuasca, 5-MeO-DMT), which are effectively prohibited outside of approved research. At the same time, pharmaceutical derivatives developed for medical...
Open access guide →Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in United Arab Emirates.